Resultados de procura - Tim Versteegen

Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial por Lars Fransecky, Walter Fiedler, Christoph Röllig, Tim Sauer, Simon Raffel, Winfried Alsdorf, Lisa Heberling, Britta Steer, Karin Huber, Tim Versteegen, Lea Spory, Dorothee Deckbar, Lena Reiser, Sonja Bendig, Lorenz Bastian, Cecilia Bozzetti, Thomas Beder, Martin Neumann, Monika Brüggemann, Nicola Gökbuget, Claudia Baldus

Ligazón do recurso